Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stemirac
- Development stage
- Unknown
- Lead developer
- NIPRO
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Stemirac (also referred to as Stemilac or STR01) is an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Sapporo Medical University in collaboration with Nipro Corporation. It is a regenerative medicine product that involves extracting bone marrow from a patient, expanding the mesenchymal stem cells ex vivo in a medium containing the patient's own serum, and then intravenously administering the expanded cells back into the same patient. Stemirac is designed to promote neural repair and functional recovery following neurological injury. In 2018, it became the first regenerative medicine product to receive conditional and time-limited approval in Japan for the treatment of spinal cord injury. The therapy's mechanism of action is thought to involve the migration of MSCs to the site of injury, where they release neurotrophic factors (such as BDNF and VEGF), modulate the inflammatory response, and support angiogenesis and endogenous tissue repair processes. It is also being investigated for other indications, including stroke and traumatic brain injury.
- Brand names
- StemiracStemilac
- Other names
- autologous bone marrow-derived mesenchymal stem cellsniprocelStemirac Injection
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)CXCR4 (C-X-C motif chemokine receptor 4)FGFR (FGFR family)GFRα1 (Glial cell line-derived neurotrophic factor receptor alpha 1)IGF-1R (Insulin-like growth factor 1 receptor)IL-6R (Interleukin-6 receptor subunit alpha)TGFBR (TGF-beta receptor)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)NGFR (p75NTR)
Beyond the preview
Go deeper on Stemirac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stemirac.